Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction

Clovis Oncology Inc.

www.clovisoncology.com

Latest From Clovis Oncology Inc.

Bookmark
  • Analysis

Finance Watch: A Rough Week To End A Bad Month For Biotech Stocks

By Mandy Jackson

Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.

Financing Business Strategies
Bookmark
  • News

New Keytruda Combo Wins Funding In England For NSCLC

By Neena Brizmohun

MSD’s Keytruda will be paid for through the Cancer Drugs Fund for use in combination with carboplatin and paclitaxel as a first-line treatment for metastatic squamous non-small-cell lung cancer.

United Kingdom Reimbursement
Bookmark
  • News

PROfound Puts Lynparza On Track For Prostate Cancer Indication

By Sten Stovall

AstraZeneca and Merck & Co said their PARP inhibitor Lynparza has become the first to show positive Phase III trial data in metastatic castration-resistant prostate cancer, putting pressure on rival Clovis’s Rubraca.

Clinical Trials Companies
Bookmark
  • Analysis

Oncology Market Leaders Maintain Their Upper Hand

By Jessica Merrill
Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts. 
Strategy Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Clovis Oncology Inc.
  • Senior Management
  • Patrick Mahaffy, Pres. & CEO
    Dan Muehl, EVP, Fin.
    Lindsey Rolfe, EVP, Clin. & Preclinical & Dev. & CMO
  • Contact Info
  • Clovis Oncology Inc.
    Phone: (303) 625-5000
    5500 Flatiron Parkway
    Boulder, CO 80301
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By